Ocugen, Inc.: exclusive license for OCU400 and special meeting postponed

What happened

• Ocugen, Inc. entered into an Exclusive License Agreement with Roots Pharmaceutical Company WLL on Oct 13, 2026 granting Roots an exclusive, non‑sublicensable, royalty‑bearing license to make, manufacture, import, export, distribute, use, keep, sell, or offer for sale OCU400 for gene therapy treatment of retinitis pigmentosa in certain countries in the Middle East and North Africa (the Territory). On Oct 13, 2026 Ocugen and Roots also entered into a commercial supply agreement under which Ocugen will manufacture and supply the licensed product to Roots. On Oct 14, 2026 the company issued a press release announcing the License Agreement.
• On Oct 14, 2026 the board of directors determined to postpone the Special Meeting of Stockholders, which had been adjourned to Oct 26, 2026, solely with respect to Proposal 1 (to increase authorized common shares by 250,000,000 shares); the Special Meeting is rescheduled for Tue, Dec 22, 2026 at 8:00 am Eastern, to be held virtually, and the new record date is close of business on Oct 30, 2026.

Key details

• Ocugen will receive an up‑front license fee and potential regulatory and development milestone payments of up to $4,000,000 in the aggregate, plus payments upon achievement of certain sales milestones of up to $255,000,000, and a royalty of 22% on net sales in the Territory.
• Roots will have sole control over preparing, filing and maintaining regulatory submissions and communicating with regulatory authorities in the Territory; Ocugen will own the global safety database for the licensed product.
• The License Agreement and the licenses granted thereunder will continue until the last to occur of: (a) the 20 year anniversary of the date of the first commercial sale of the licensed product in the Territory; (b) the expiration of the last valid claim of a licensor patent right in the Territory; and (c) the expiration of market exclusivity, including any regulatory exclusivity, in the Territory. The agreement also contains customary termination provisions for uncured material breach and certain corporate events.
• The company intends to file Definitive Additional Materials on Schedule 14A related to the Special Meeting and noted the proxy statement was filed on Jul 30, 2026; the filing also states that stockholders are urged to read those materials.

Why it may matter

• The 8-K reports an Item 1.01 material definitive agreement (the Exclusive License Agreement and related commercial supply agreement), an Item 7.01 Regulation FD disclosure (press release), and an Item 8.01 other event (postponement of the Special Meeting and new record date). It describes the license scope, payment terms, royalty rate, regulatory responsibilities, contract term triggers, and the rescheduled Special Meeting date and record date.
  A filing does not show why the insider traded or why the company acted.